Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)

ClinicalTrials.gov ID: NCT07816224

Public ClinicalTrials.gov record NCT07816224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Masked, Vehicle-Controlled, Two-Period Crossover Study of Atropine Sulfate Ophthalmic Solution (0.005% w/v) for the Treatment of Symptoms of Epiphora

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study tests whether a very low concentration of atropine eye drops (0.005%) reduces excessive tearing (epiphora) in adults. Each participant will use two different eye drops, one at a time: the atropine drop and an identical-looking drop with no active ingredient (vehicle). Each drop is used once nightly for 7 days, with about 2 weeks between the two treatment periods. Neither the participant nor the study doctor will know which drop is being used during each period. The main measure is the change in how often participants need to wipe their eyes because of tearing. About 12 to 18 adults will take part.

Study identification

NCT ID
NCT07816224
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Rehan Ahmed
Other
Enrollment
16 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2026 (Estimated)
Primary completion
Nov 2026 (Estimated)
Completion
Nov 2026 (Estimated)
Last update posted
Oct 14, 2026

2026

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
2
Facility City State ZIP Site status
Greater Houston Eye Consultants Houston Texas 77401 Recruiting
North Texas Eye Specialists Mesquite Texas 75150 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07816224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2026 · Synced Oct 15, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07816224 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →